Link: Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023
Link: Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023
Excerpt from: Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer
Follow this link: FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete...
Read more: Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
Read the original: Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
Continued here: Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of...
Read more from the original source: NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results
Excerpt from: Codexis Reports Second Quarter 2023 Financial Results
Read the rest here: Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
Originally posted here: Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive...
Recent Comments